<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients
Image Overlay - Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Announces First Patient Dosed in Phase II Study of Istaroxime in Heart Failure Patients

Windtree Therapeutics, Inc. announced that it has dosed the first patient in its phase II study of istaroxime in patients experiencing early cardiogenic shock. Early cardiogenic shock is one of two developmental programs for istaroxime, with the other program targeting acute heart failure, which is supported by positive phase IIOa and IIb trial results and a FDA Fast Track designation. Fast Track programs put an extra strain on clinical trials logistics, but Yourway is prepared for such challenges.

Back to Index
Media

Upcoming Events

Precision in Pharma Supply Chain & Logistics Summit (Munich)

April 15-16, 2024
Science Congress Center Munich

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Media

Articles

The At-home Trial Experience: Leveraging value-chain to reach and retain patients

Open chat
Come chat with us!
Hello! How can I help you?